FGF类似物在代偿性MASH肝硬化中的疗效与安全性:系统评价与Meta分析
该系统评价与Meta分析纳入5项RCT共589例代偿性(F4)MASH肝硬化成人患者,评估FGF类似物对比安慰剂的疗效。FGF类似物未显著改善主要终点(纤维化改善≥1期且MASH不恶化),但改善MASH消退及ELF评分、Pro-C3、肝硬度等非侵入性纤维化指标,不良事件相关停药更频繁。
要点
- FGF类似物未显著改善纤维化改善≥1期且MASH不恶化的主要终点(RR 1.32,95%CI 0.89–1.97)。
- FGF21类似物在事后分析中提高MASH消退率(RR 3.17,95%CI 1.49–6.73),但MASH消退且纤维化不恶化仍不确定。
- FGF类似物降低ELF评分、Pro-C3和肝硬度,但不良事件相关停药风险增加(RR 3.44,95%CI 1.13–10.43)。
核心结论
- FGF类似物未显著改善代偿性MASH肝硬化的主要纤维化终点,但改善MASH消退及非侵入性纤维化指标,支持继续开展更长随访的3期试验。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Embase、CENTRAL和ClinicalTrials.gov至2026年7月8日,纳入5项对比FGF类似物与安慰剂的RCT,共589例代偿性(F4)MASH肝硬化成人患者。
主要发现
- FGF类似物未显著改善纤维化至少1期且MASH不恶化(RR 1.32;95%CI 0.89–1.97)。
- 事后探索性分析中,FGF21类似物提高MASH消退率(RR 3.17;95%CI 1.49–6.73),但MASH消退且纤维化不恶化仍不确定(RR 1.75;95%CI 0.95–3.23)。
- FGF类似物降低ELF评分(MD −0.52;95%CI −0.79至−0.25)、Pro-C3(MD −26.49个百分点;95%CI −40.47至−12.51)和肝硬度(MD −2.30 kPa;95%CI −3.90至−0.71)。
- 严重不良事件未显著增加,但不良事件相关停药更频繁(RR 3.44;95%CI 1.13–10.43)。
- FGF19相关结果仅来自单一项aldafermin试验。
临床怎么用
- 在代偿性MASH肝硬化患者中,FGF类似物可能改善MASH消退及非侵入性纤维化指标,但需关注不良事件相关停药风险。
局限性
- FGF19相关发现仅基于单一项试验(aldafermin),证据有限。
- MASH消退及部分分析为事后探索性分析,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Background and Aims Compensated MASH cirrhosis is an advanced disease with no current approved pharmacologic therapy. FGF analogues have shown biological activity, but individual trials have not established histologic efficacy. We aim to evaluate their effects across histologic and non-invasive outcomes in this population. Methods PubMed, Embase, CENTRAL and ClinicalTrials.gov were searched from inception through 8 July 2026 for RCTs comparing FGF analogues with placebo in adults with compensated (F4) MASH cirrhosis. The primary outcome was at least 1-stage fibrosis improvement without MASH worsening. Secondary outcomes included Pro-C3, Enhanced Liver Fibrosis (ELF) score and liver stiffness. MASH resolution and safety were exploratory. Random-effects meta-analyses were performed. RoB 2 and GRADE assessments were conducted. Results Five RCTs involving 589 participants were included. FGF analogues did not significantly improve fibrosis by at least one stage without worsening of MASH (RR, 1.32; 95% CI, 0.89–1.97). In post hoc exploratory analyses, FGF21 analogues increased MASH resolution alone (RR, 3.17; 95% CI, 1.49–6.73), whereas resolution without worsening of fibrosis remained inconclusive (RR, 1.75; 95% CI, 0.95–3.23). Treatment reduced ELF score (MD, −0.52; 95% CI, −0.79 to −0.25), Pro-C3 (MD, −26.49 percentage points; 95% CI, −40.47 to −12.51) and liver stiffness (MD, −2.30 kPa; 95% CI, −3.90 to −0.71). Serious adverse events were not significantly increased, but adverse-event-related discontinuation was more frequent (RR, 3.44; 95% CI, 1.13–10.43). FGF19 findings derive from a single trial (aldafermin). Conclusions FGF analogues did not significantly improve the primary fibrosis endpoint, but improved MASH resolution and non-invasive fibrosis measures, supporting continued evaluation of FGF analogues in Phase 3 trials with longer follow-up.
引用
- Diabetes, Obesity and Metabolism:Therapeutic Signals Without Histologic Certainty: FGF Analogues in Compensated MASH Cirrhosis—A Systematic Review and Meta‐Analysis
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。